# Targeting endolysosomal trafficking to increase delivery of antisense oligonucleotides to tumors

> **NIH NIH F31** · UNIVERSITY OF CALIFORNIA-IRVINE · 2021 · $18,445

## Abstract

PROJECT SUMMARY/ABSTRACT
Antisense oligonucleotides (ASO) are the ultimate platform technology that could cripple lethal, drug-resistant
tumors by targeting “undruggable” oncogenes. ASO are 16-20 bp nuclease-resistant oligonucleotides that base
pair with a target RNA and can elicit its degradation or alter its splicing. Despite its great potential in cancer
therapy, poor uptake into tumor cells currently limits the clinical use of ASO in cancer patients. The long-term
goal of the Edinger lab is to use our knowledge of endolysosomal trafficking to develop novel, effective, and
minimally toxic therapies for cancer and other diseases. The overall objective of this proposal is to develop
novel approaches that increase ASO activity in tumors and normal tissues. The central hypothesis is that
simultaneously inhibiting endocytic recycling and lysosomal fusion will increase ASO activity in tumor and
normal tissues by trapping ASO in the pre-lysosomal compartment from which ASO escape is most efficient.
Under the first aim, it will be determined whether oral administration of a small molecule that enhances ASO
activity in vitro also increases ASO activity in tumors. Under the second aim, a candidate approach will be used
in conjunction with cutting-edge genetic tools to identify which of the known molecular targets of a second
molecule are responsible for ASO potentiation and endolysosomal trafficking disruption. The rationale for this
project is that small molecules that increase ASO activity in tumors could yield major benefits to patients with
aggressive, drug-resistant tumors by improving the efficacy of oncology ASO in late stages of clinical
development and stimulating development of new ASO. The proposed research is expected to have a
profound positive impact by establishing the feasibility of using small molecules to make oncology ASO
clinically viable and stimulating development of new ASO for cancer therapy.
The overall training objective in this application is to develop and cultivate the management, networking,
translational, and writing skills that are necessary to be successful in a postdoctoral fellowship and as an
academic PI at a major research institution. The Training Plan addresses these training goals by taking
advantage of critical resources provided by UCI and its vibrant, collaborative cancer research community.

## Key facts

- **NIH application ID:** 10236196
- **Project number:** 1F31CA261085-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Brendan Tyler Finicle
- **Activity code:** F31 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $18,445
- **Award type:** 1
- **Project period:** 2021-04-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10236196

## Citation

> US National Institutes of Health, RePORTER application 10236196, Targeting endolysosomal trafficking to increase delivery of antisense oligonucleotides to tumors (1F31CA261085-01). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10236196. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*